EFFECTIVENESS AND SAFETY OF CYD-TDV VACCINE IN CHILDREN

Authors

  • Sonny Edbert Universitas Surabaya
  • Hotimah Masdan Salim Universitas Nahdlatul Ulama Surabaya

DOI:

https://doi.org/10.31004/jkt.v4i3.17156

Keywords:

CYD-TDV Vaccine, Dengue Disease, Dengue Virus

Abstract

Dengue virus is classified as an arbovirus and its incidence rate continues to grow, especially in children in the last few years recorded by WHO. In the absence of specific therapy to treat dengue, prevention with vaccination is the right choice, especially for Asia and endemic regions such as Indonesia. Until now, the vaccine for dengue is only available in one commercial formulation (CYD-TDV) which has been licensed and developed by Sanofi Pasteur. The purpose of this study is to determine the effectiveness and safety of the CYD-TDV vaccine for children in endemic areas. The method used in this study is a literature search. Conducted meta-analyses and systematic reviews published between 2017 and 2020 identified in MEDLINE, especially in children based on inclusion and exclusion criteria. The findings obtained are Immunogenicity in the test group vaccinated with CYD-TDV was higher than the control group and side effects between two groups were not significant. So it can be concluded CYD-TDV vaccine is effective and safe for children’s in endemic areas. This conclusion is the basis for further vaccine development, especially for Asian regions, such as Indonesia.

References

Agarwal, R., Wahid, M. H., Yausep, O. E., Angel, S. H., & Lokeswara, A. W. (2017). The immunogenicity and safety of CYD-tetravalent dengue vaccine (CYD-TDV) in children and adolescents: a systematic review. Acta Med Indones, 49(1), 24–33.

Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., & Sankoh, O. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504–507.

da Silveira, L. T. C., Tura, B., & Santos, M. (2019). Systematic review of dengue vaccine efficacy. BMC Infectious Diseases, 19, 1–8.

Godói, I. P., Lemos, L. L. P., De Araújo, V. E., Bonoto, B. C., Godman, B., & Guerra Junior, A. A. (2017). CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of Comparative Effectiveness Research, 6(2), 165–180.

Harapan, H., Michie, A., Mudatsir, M., Sasmono, R. T., & Imrie, A. (2019). Epidemiology of dengue hemorrhagic fever in Indonesia: analysis of five decades data from the National Disease Surveillance. BMC Research Notes, 12, 1–6.

Rosa, B. R., da Cunha, A. J. L. A., & de Andrade Medronho, R. (2019). Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis. BMJ Open, 9(3), e019368.

World Health Organization. (2012). World Health Organization, and UNICEF. Handbook for clinical management of dengue.

World Health Organization. (2015). National guidelines for clinical management of dengue fever. World Health Organization.

Downloads

Published

2023-09-07

How to Cite

Edbert, S., & Salim, H. M. (2023). EFFECTIVENESS AND SAFETY OF CYD-TDV VACCINE IN CHILDREN. Jurnal Kesehatan Tambusai, 4(3), 2380–2386. https://doi.org/10.31004/jkt.v4i3.17156